UroGen Pharma Ltd. (URGN): Depreciation & Amortization
$307.0K
Year ended 2025-12-31
$308.0K
Trailing 12 months to 2026-06-30
-30.7%
3-year compound annual growth
-5.9%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $307.0K | -6.7% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $329.0K | -59.0% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $802.0K | -13.2% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $924.0K | +11.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $831.0K | +99.8% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $416.0K | n/c | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $300.0K | -25.0% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $400.0K | +100.0% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $200.0K | 0.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $200.0K | n/a | 2019-02-28, From 2016-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $307.0K | -6.7% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $4.05M | -36.5% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
| Xencor Inc (XNCR) | 2025-12-31 | $10.51M | -13.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $562.6K | +4.5% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.03M | +0.9% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $10.12M | +6.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $9.26M | -26.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $1.37M | n/m |
Compare URGN, ZVRA, GYRE, XNCR side by side · Screen every company in Pharmaceutical Preparations ↗